Analysts Set Sagimet Biosciences Inc. (NASDAQ:SGMT) PT at $25.57

Sagimet Biosciences Inc. (NASDAQ:SGMT) has received an average rating of “Moderate Buy” from the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $26.3333.

A number of analysts have recently issued reports on SGMT shares. Guggenheim decreased their target price on Sagimet Biosciences from $27.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. Canaccord Genuity Group raised their price target on shares of Sagimet Biosciences from $49.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sagimet Biosciences in a research report on Friday, July 17th. Citizens Jmp decreased their price objective on shares of Sagimet Biosciences from $35.00 to $12.00 and set a “market outperform” rating for the company in a research note on Tuesday, May 19th. Finally, Oppenheimer reissued an “outperform” rating on shares of Sagimet Biosciences in a research report on Friday, May 1st.

Insider Buying and Selling

In related news, CEO David Happel sold 64,051 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $7.76, for a total value of $497,035.76. Following the completion of the sale, the chief executive officer directly owned 741,570 shares in the company, valued at approximately $5,754,583.20. This represents a 7.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Elizabeth Rozek sold 10,545 shares of the firm’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $7.76, for a total value of $81,829.20. Following the completion of the transaction, the insider directly owned 224,414 shares in the company, valued at $1,741,452.64. This trade represents a 4.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 113,646 shares of company stock valued at $920,491. Company insiders own 11.50% of the company’s stock.

Hedge Funds Weigh In On Sagimet Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in Sagimet Biosciences by 4.3% in the third quarter. Vanguard Group Inc. now owns 1,203,231 shares of the company’s stock valued at $8,254,000 after acquiring an additional 49,375 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in shares of Sagimet Biosciences by 228.1% during the fourth quarter. Affinity Asset Advisors LLC now owns 1,148,245 shares of the company’s stock worth $6,798,000 after purchasing an additional 798,245 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Sagimet Biosciences during the fourth quarter worth $4,620,000. Millennium Management LLC boosted its stake in shares of Sagimet Biosciences by 6,484.7% in the third quarter. Millennium Management LLC now owns 776,377 shares of the company’s stock valued at $5,326,000 after purchasing an additional 788,537 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Sagimet Biosciences by 82.6% in the first quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock valued at $3,268,000 after purchasing an additional 282,969 shares during the period. 87.86% of the stock is owned by institutional investors and hedge funds.

Sagimet Biosciences Trading Down 1.4%

SGMT stock opened at $9.39 on Thursday. The stock has a 50-day moving average price of $7.39 and a two-hundred day moving average price of $6.52. Sagimet Biosciences has a 12-month low of $4.50 and a 12-month high of $10.06. The company has a market cap of $305.93 million, a PE ratio of -7.34 and a beta of 3.37.

Sagimet Biosciences (NASDAQ:SGMT) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Equities analysts forecast that Sagimet Biosciences will post -1.15 EPS for the current fiscal year.

Key Stories Impacting Sagimet Biosciences

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: Canaccord raises price target: Canaccord Genuity lifted its target for Sagimet from $49 to $56 and maintained a “buy” rating, implying substantial potential upside from recent trading levels. The upgrade reflects a bullish view of the company’s development prospects. Benzinga analyst price target report
• Positive Sentiment: Progress on denifanstat: Wedbush Securities said Sagimet is making “good progress” toward bringing denifanstat to U.S. patients. Positive commentary on the company’s lead drug candidate could support sentiment because future valuation depends heavily on clinical and regulatory execution. Sagimet making progress on denifanstat
• Neutral Sentiment: Short-interest data appears unreliable: Reported short interest was zero shares, unchanged from the prior period, with a zero days-to-cover ratio. Because the figures include an undefined percentage change and may reflect incomplete reporting, they provide little meaningful insight into trading pressure.
• Negative Sentiment: Quarterly loss slightly exceeded expectations: Sagimet reported a second-quarter 2026 loss of $0.26 per share, compared with analysts’ expectation of a $0.25 loss. The modest earnings miss reinforces that the company remains loss-making while it advances its pipeline. Sagimet second-quarter 2026 results
• Negative Sentiment: Director reduced holdings: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. While insider sales can be routine, the transaction may weigh on sentiment because it signals reduced personal exposure by a company director.

Sagimet Biosciences Company Profile

Sagimet Biosciences (NASDAQ: SGMT) is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company’s lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101’s potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.